바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.77 No.2
Citation Share

A Case of Venlafaxine-Induced Interstitial Lung Disease

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2014, v.77 no.2, pp.81-84







& (2014). A Case of Venlafaxine-Induced Interstitial Lung Disease. Tuberculosis & Respiratory Diseases, 77(2), 81-84.
  • Downloaded
  • Viewed
PDF Download

Abstract

A patient treated with venlafaxine for major depression developed an interstitial lung disease (ILD) with the characteristic clinical, radiological and pathological features of chronic hypersensitivity pneumonitis. A high resolution computed tomography scan demonstrated ground glass opacity, mosaic perfusion with air-trapping and traction bronchiectasis in both lungs. The pathological findings were consistent with a nonspecific interstitial pneumonia pattern. Clinical and radiological improvements were noted after the discontinuation of venlafaxine and the administration of a corticosteroid. This report provides further evidence that the anti-depressant venlafaxine can cause ILD.

keywords
Hypersensitivity, Pneumonia, Lung Disease, Interstitial, Venlafaxine

Reference

1.

1. Paparrigopoulos T, Tzavellas E, Karaiskos D, Ilias I, Liappas I. Acute eosinophilic pneumonia after venlafaxine overdose. J Clin Psychopharmacol 2011;31:258-9.

2.

2. Turner RC, Nelson JE, Roberts BT, Gillam DM. Venlafaxine-associated interstitial pneumonitis. Pharmacotherapy 2005;25:626-9.

3.

3. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55 Suppl A:62-8.

4.

4. Andrews JM, Ninan PT, Nemeroff CB. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 1996;4:48-56.

5.

5. Melien O, Skaali T, Myhr K, Brors O. Venlafaxine and asthma. Nord J Psychiatry 2005;59:538-40.

6.

6. Tsigkaropoulou E, Hatzilia D, Rizos E, Christodoulou C, Loukides S, Papiris S, et al. Venlafaxine-induced acute eosinophilic pneumonia. Gen Hosp Psychiatry 2011;33:411.e7-9.

7.

7. Fleisch MC, Blauer F, Gubler JG, Kuhn M, Scherer TA. Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment. Eur Respir J 2000;15:205-8.

8.

8. Drent M, Singh S, Gorgels AP, Hansell DM, Bekers O, Nicholson AG, et al. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am J Respir Crit Care Med 2003;167:958-61.

9.

9. Arias SA, Cohen P, Kwon JS. Clozapine-induced lymphocytic alveolitis. Am J Psychiatry 2011;168:210-1.

10.

10. Gonzalez-Rothi RJ, Zander DS, Ros PR. Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest 1995;107:1763-5.

11.

11. Borderias Clau L, Marigil Gomez MA, Val Adan P, Marcen Letosa M, Biescas Lopez R, Garrapiz Lopez FJ. Hypersensitivity pneumonitis due to venlafaxine. Arch Bronconeumol 2008;44:571-3.

12.

12. Patel RA, Sellami D, Gotway MB, Golden JA, Webb WR. Hypersensitivity pneumonitis: patterns on high-resolution CT. J Comput Assist Tomogr 2000;24:965-70.

13.

13. Barrera L, Mendoza F, Zuniga J, Estrada A, Zamora AC, Melendro EI, et al. Functional diversity of T-cell subpopulations in subacute and chronic hypersensitivity pneumonitis. Am J Respir Crit Care Med 2008;177:44-55.

14.

14. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy